Diagnosis and treatment of metastatic and castration resistant prostate cancer became more and more and complex due to the increasing knowledge and understanding of the underlying molecular events and the subsequently deducted innovative medical treatment.
Modern imaging studies in CRPC have become more selective and currently include positron emission tomography, whole body magnetic resonance imaging, immunoscintigraphy besides the traditional studies such as bone scans and computed tomography.
Interviews from EAU 2015, Madrid, Spain
Interview with Prof. Declan G. Murphy during EAU 2015, Madrid, Spain
Interview with Prof. Manfred P. Wirth during EAU 2015, Madrid, Spain
Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate
Attard G, De Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Joshua AM, et al.Clin Cancer Res. 2015 Apr 1;21(7):1621-7.
Merseburger AS, Scher HI, Bellmunt J, Miller K, Mulders PFA, Stenzl A, et al.BJU Int. 2015 Jan;115(1):41-9.
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme.
Caffo O, De Giorgi U, Fratino L, Lo Re G, Basso U, D'Angelo A, et al.BJU Int. 2015 May;115(5):764-71.
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL)
Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, et al.Lancet Oncol. 2015 May;16(5):509-21
About the editors
- Professor Miller has been Chairman and Professor of Urology for the Department of Urology at the Benjamin Franklin Medical Center, Berlin, Germany, since 1993. In 2007 he became Chairman of the Department of Urology for the entire Charité (Campus Benjamin Franklin, Campus Mitte and Campus Virchow Klinikum). With more than 6000 in-patients per year, the Dep. of Urology at the Charité is one the largest urologicals clinics in Europe.
- Prof Axel S. Merseburger is currently Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany, having previously served as Vice Chairman of the Department of Urologic Oncology and Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Professor Merseburger obtained his medical degree from Hannover Medical School in 2002 following a 1-year academic research programme in Washington D.C., USA, where he finished his M.D. thesis.
- Jun 201528Jul 201530Contact: ICS Offi ce Tel.: +44 117 944 4881 Fax: +44 117 944 4882 E-mail: info@icsoffi ce.org
- Jul 20155Jul 201511Salzsburg, Austria Contact: European School of Urology (ESU) Tel.: +31 26 389 0680 Fax: +31 26 389 0674 E-mail: email@example.com